Dr. Giralt on the Evaluation of Ide-cel in Triple-Class Exposed R/R Myeloma
February 27th 2023Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.
Read More